“An effective and safe pharmaceutical innovation, which will give many young men the possibility of being able to face the path towards reversing the baldness process with less fear.”
With these words Dr. Stefano Fatelli, general manager of Cantabria Labs Difa Cooper, the Italian branch of the Spanish multinational Cantabria Labs, announces a novelty in the field of dermatology 20 years after the introduction of oral finasteride: the first topical finasteride authorized in Italy able to act in a targeted manner on the hair bulb, limiting possible side effects.
A pharmaceutical innovation project in line with the values of the Cantabria Labs group of innovation and entrepreneurial spirit and which allows Cantabria Labs Difa Cooper, to consolidate its commitment alongside dermatologists to offer solutions capable of improving the lives of who is affected by androgenetic alopecia, a condition that often significantly affects social life.
